Telmisartan and hydrochlorothiazide combination therapy

a technology of telmisartan and hydrochlorothiazide, which is applied in the field of pharmaceuticals, can solve the problems of difficult measurement of renin, difficult to measure pra and prc, and not in all patients the target blood pressure level is achieved, so as to increase the risk of myocardial infarction, increase blood pressure, and double the risk of cardiovascular diseases

Inactive Publication Date: 2006-07-20
BOEHRINGER INGELHEIM INT GMBH
View PDF0 Cites 32 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0006] There exists a striking relationship between high blood pressure and cardiovascular morbidity and mortality, i.e., an increased risk of myocardial infarction, heart failure, stroke, or kidney disease in case of increased blood pressure. An incremental increase of 20 mmHg in systolic or 10 mmHg in

Problems solved by technology

Unfortunately a subgroup of hypertensive patients does still not adequately respond to treatment with an ARB or a combination therapy of an ARB plus a low dose diuretic, meaning that not in all patients the target blood pressure levels are achieved as suggested by the most recent guidelines, especially f

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Telmisartan and hydrochlorothiazide combination therapy
  • Telmisartan and hydrochlorothiazide combination therapy

Examples

Experimental program
Comparison scheme
Effect test

example 1

Surprising Responder Rate Using 80 mg Telmisartan+25 mg HCTZ

[0083] An important goal of up-titrating antihypertensive medication is to increase the number of patients adequately responding to treatment. Surprisingly improved responder rates have become obvious when the current clinical database of telmisartan was analyzed, in particular with respect to compare the responder rates upon treatment with telmisartan 80 mg / HCTZ 25 mg to those with telmisartan 80 mg / HCTZ 12.5 mg. Responders are defined as having DBP <90 mmHg or a reduction of at least 10 mmHg. Regarding SBP an adequate response is defined as SBP <140 or a reduction of at least 10 mmHg. When comparing telmisartan 80 mg / HCTZ 25 mg with telmisartan 80 mg / HCTZ 12.5 mg and applying the above mentioned definitions the diastolic (DBP) response rates increased by 6.6% for patients in controlled studies and by 15.4% for patients from follow-up studies. Systolic (SBP) response rates improved by 7.8% for patients from controlled and...

example 2

Composition of a 680 mg Total Weight Bilayer Tablet Comprising 80 mg of Telmisartan and 25 mg of HCTZ

[0088]

Ingredientmg per tabletTelmisartan Layer:Telmisartan80.000Sodium hydroxide6.720Polyvidone K2524.000Meglumine24.000Purified water(400.000)Sorbitol337.280Magnesium stearate8.000Total Telmisartan Layer480.000Hydrochlorothiazide Layer:Hydrochlorothiazide25.000Lactose monohydrate99.100Microcrystalline cellulose64.000Maize starch6.000Ferric oxide0.900Sodium starch glycolate4.000Purified water(64.000)Magnesium stearate1.000Total Hydrochlorothiazide Layer200.000

example 3

Confirmation of the Surprisingly High Responder Rate Using 80 mg of Telmisartan+25 mg of HCTZ in a Separate Clinical Trial

[0089] To confirm the surprising responder rate of 80 mg telmisartan+25 mg HCTZ found upon analyzing the available clinical telmisartan database, the corresponding responder rate was determined for a clinical trial actually designed to compare the safety and efficacy of a 80 mg telmisartan+25 mg hydrochlorothiazide combination with the currently available 160 mg valsartan+25 mg hydrochlorothiazide combination in patients with Stage 1 and Stage 2 hypertension (confirmation study). This study was a randomized, double-blind, double-dummy, placebo-controlled, forced-titration trial, with a total duration of up to 12 weeks (eight weeks active treatment). The target population included both male and female hypertensive patients, at least 18 years of age.

[0090] The primary objective of this study was to show that the combination of MICARDIS® HCT (telmisartan 80 mg / hyd...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Massaaaaaaaaaa
Massaaaaaaaaaa
Login to view more

Abstract

A pharmaceutical composition comprising about 80 mg of telmisartan or a salt thereof and about 25 mg of hydrochlorothiazide or about 160 mg of telmisartan or a salt thereof and about 50 mg of hydrochlorothiazide, and methods of treating hypertension in patients with such combination.

Description

RELATED APPLICATIONS [0001] This application claims benefit of U.S. Ser. No. 60 / 637,062, filed Dec. 17, 2004, which is hereby incorporated by reference in its entirety.FIELD OF THE INVENTION [0002] The present invention relates to a pharmaceutical composition comprising as active ingredients about 80 mg of the angiotensin II receptor antagonist (ARB) telmisartan and about 25 mg of the diuretic hydrochlorothiazide (HCTZ) and a pharmaceutical composition which comprises about 160 mg telmisartan and about 50 mg hydrochlorothiazide and can be split into halves. The composition is used to treat hypertension in patients with an insufficient blood pressure reduction upon treatment either with an angiotensin II receptor antagonist, due to low plasma levels of renin or with a pharmaceutical composition of an angiotensin II receptor antagonist and lower doses of hydrochlorothiazide. BACKGROUND OF THE INVENTION [0003] Telmisartan, a white to slightly yellowish solid, is an angiotensin II recep...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/549A61K31/41A61K9/20
CPCA61K9/209A61K31/41A61K31/549A61K2300/00A61P9/12
Inventor SCHUMACHER, HELMUT E.RIEDEL, AXELBOEHM, PETER
Owner BOEHRINGER INGELHEIM INT GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap